BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fabhalta (Iptacopan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fabhalta (Iptacopan)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06388941-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Fabhalta (Iptacopan): Phase 2 readout est. (NCT06388941)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 2.\nStudy: Iptacopan in Patients W
 ith ANCA Associated Vasculitis\nEstimated primary completion: 30 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/iptacopan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06388941
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04817618-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04817618)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Study of Efficacy and S
 afety of Iptacopan in Patients With C3 Glomerulopathy.\nEstimated primary 
 completion: 29 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iptacopan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04817618
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517758-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06517758)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Generalized Myasthenia Gravis.
 \nStudy: A Phase III Study to Investigate Efficacy\, Safety and Tolerabili
 ty of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years 
 With gMG.\nEstimated primary completion: 30 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06517758
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747613-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04747613)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Long-term Safety and Tolerability of Iptacopan in Patients 
 With Paroxysmal Nocturnal Hemoglobinuria\nEstimated primary completion: 18
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iptaco
 pan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04747613
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797518-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271127
DTEND;VALUE=DATE:20271128
SUMMARY:Fabhalta (Iptacopan): Phase 2 readout est. (NCT06797518)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 2\, IgA Nephropathy.\nStudy: Study
  to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Ki
 dneys of Adult Patients With IgAN\nEstimated primary completion: 27 Novemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/iptacopan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067975
 18
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347990-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Fabhalta (Iptacopan): Phase na readout est. (NCT07347990)
DESCRIPTION:Fabhalta (Iptacopan)\, phase na.\nStudy: Safety and Efficacy of
  Iptacopan in Patients With High-Risk Transplantation-Associated Thromboti
 c Microangiopathy\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07347990
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05935215-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280721
DTEND;VALUE=DATE:20280722
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT05935215)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Efficacy and Safety of 
 Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study 
 Participants With Atypical Hemolytic Uremic Syndrome (aHUS)\nEstimated pri
 mary completion: 21 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/iptacopan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05935215
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05755386-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281027
DTEND;VALUE=DATE:20281028
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT05755386)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Study of Efficacy and S
 afety of Iptacopan in Participants With IC-MPGN\nEstimated primary complet
 ion: 27 October 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /iptacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05755386
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994845-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06994845)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, IgA Nephropathy.\nStudy: Study
  to Assess the Efficacy\, Pharmacokinetics\, Safety and Tolerability of Ip
 tacopan in Pediatric Patients With Primary IgAN\nEstimated primary complet
 ion: 28 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 tacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06994845
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557462-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20301204
DTEND;VALUE=DATE:20301205
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04557462)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Rollover Extension Program (REP) to Evaluate the Long-term Safety and 
 Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary I
 gA Nephropathy\nEstimated primary completion: 4 December 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04557462
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934967-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20311014
DTEND;VALUE=DATE:20311015
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06934967)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study to Assess the Pharmacokinetics\, Safety\, and Tolerab
 ility of Iptacopan in Pediatric PNH Patients\nEstimated primary completion
 : 14 October 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 tacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06934967
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05795140-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20320716
DTEND;VALUE=DATE:20320717
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT05795140)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Evaluate Long-term Safe
 ty\, Tolerability and Efficacy of Iptacopan in Study Participants With aHU
 S\nEstimated primary completion: 16 July 2032. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/iptacopan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05795140
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03955445-887@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20360530
DTEND;VALUE=DATE:20360531
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT03955445)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Long-term Efficacy\, Sa
 fety and Tolerability of Iptacopan in C3G or IC-MPGN\nEstimated primary co
 mpletion: 30 May 2036. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/iptacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03955445
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
